Last updated 12 days ago
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
1246 patients around the world
Available in Chile, Brazil, Peru, Guatemala
Merck Sharp & Dohme Corp.
28Research sites
1246Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
Recruiting
Hospital São Carlos-Oncocentro Ce
Recruiting
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica
Recruiting
Nucleo de Pesquisa da Rede Sao Camilo-Instituto Brasileiro de Controle do Cancer - IBC
Recruiting
Instituto do Câncer do Estado de São Paulo "Octavio Frias de Oliveira" - ICESP
Recruiting
Centro Pesquisas Oncologicas - CEPON
Recruiting
Centro de Investigación del Maule - Talca
Recruiting
Instituto Oncológico FALP (Fundación Arturo Lopez Perez)
Recruiting
Clínica Puerto Montt
Recruiting
James Lind Centro de Investigación del Cáncer - Temuco
Recruiting
StudyKEYVIBE-003
SponsorMerck Sharp & Dohme Corp.
Study typeInterventional
Conditions
Non-small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04738487
